The updated clinical practice guidelines for the diagnosis and management of long COVID provide recommendations for evaluating and treating patients with persistent symptoms following SARS-CoV-2 infection. Long COVID is defined as symptoms and signs persisting for more than three months after the diagnosis of COVID-19, which cannot be explained by alternative diagnoses. The guidelines emphasize the importance of a comprehensive evaluation, including medical history, physical examination, blood tests, imaging studies, and functional tests, to identify underlying causes of symptoms such as respiratory distress, chest pain, cough, fatigue, arthralgia, myalgia, headaches, cognitive impairment, anxiety, depression, sleep disorders, dysphagia, olfactory or gustatory disorders, post-exercise malaise, postural tachycardia syndrome, and other symptoms. For the treatment of long COVID, the guidelines recommend adjustments in medication, specific treatments for newly diagnosed conditions, and referrals to specialists for complex cases. For example, patients with respiratory distress should undergo heart and lung-related tests, while those with chest pain should be evaluated for cardiovascular, respiratory, musculoskeletal, and gastrointestinal conditions. Patients with cough should be assessed using criteria for chronic cough, and those with fatigue should undergo medical history-taking, physical examination, blood tests, electromyography, and 6-minute walk tests. For cognitive impairment, neurological examination and neuropsychological assessment are recommended, along with brain imaging if necessary. Patients with anxiety or depression should be referred to psychiatry for evaluation and treatment. The guidelines also address the use of anticoagulants, steroids, and anti-fibrotic drugs, emphasizing that these should be used only when necessary. Additionally, the guidelines recommend vaccination and antiviral treatment during the acute phase to reduce the risk of developing long COVID. The guidelines are based on the latest research data and expert consensus, and they are intended to assist clinicians in making appropriate decisions for the management of long COVID. The guidelines are not intended for commercial or medical review purposes but can be used for clinical and educational purposes.The updated clinical practice guidelines for the diagnosis and management of long COVID provide recommendations for evaluating and treating patients with persistent symptoms following SARS-CoV-2 infection. Long COVID is defined as symptoms and signs persisting for more than three months after the diagnosis of COVID-19, which cannot be explained by alternative diagnoses. The guidelines emphasize the importance of a comprehensive evaluation, including medical history, physical examination, blood tests, imaging studies, and functional tests, to identify underlying causes of symptoms such as respiratory distress, chest pain, cough, fatigue, arthralgia, myalgia, headaches, cognitive impairment, anxiety, depression, sleep disorders, dysphagia, olfactory or gustatory disorders, post-exercise malaise, postural tachycardia syndrome, and other symptoms. For the treatment of long COVID, the guidelines recommend adjustments in medication, specific treatments for newly diagnosed conditions, and referrals to specialists for complex cases. For example, patients with respiratory distress should undergo heart and lung-related tests, while those with chest pain should be evaluated for cardiovascular, respiratory, musculoskeletal, and gastrointestinal conditions. Patients with cough should be assessed using criteria for chronic cough, and those with fatigue should undergo medical history-taking, physical examination, blood tests, electromyography, and 6-minute walk tests. For cognitive impairment, neurological examination and neuropsychological assessment are recommended, along with brain imaging if necessary. Patients with anxiety or depression should be referred to psychiatry for evaluation and treatment. The guidelines also address the use of anticoagulants, steroids, and anti-fibrotic drugs, emphasizing that these should be used only when necessary. Additionally, the guidelines recommend vaccination and antiviral treatment during the acute phase to reduce the risk of developing long COVID. The guidelines are based on the latest research data and expert consensus, and they are intended to assist clinicians in making appropriate decisions for the management of long COVID. The guidelines are not intended for commercial or medical review purposes but can be used for clinical and educational purposes.